摘要
目的:探讨左旋多巴联合普拉克索治疗帕金森病的有效性及安全性。方法:120例帕金森病患者随机分为研究组和对照组各60例,对照组单纯给予左旋多巴用药,研究组联合应用普拉克索和左旋多巴,且左旋多巴较对照组减量,观察两组治疗后帕金森病量表(UPDRS)、汉密尔顿抑郁量表(HAMD)评分及不良反应情况。结果:治疗后研究组4型UPDRS评分均明显低于对照组,HAMD评分明显低于对照组,提示研究组患者帕金森病症状明显轻于对照组,抑郁情绪明显轻于对照组(P<0.05)。研究组治疗过程中不良反应发生率明显低于对照组(P<0.01)。结论:普拉克索联合左旋多巴治疗帕金森病具有较好的临床疗效和安全性,适合于推广应用。
Objective：To discuss the effectiveness and safety of levodopa combined with pramipexole in the treatment of Parkinson＆#39;s disease.Methods：120 patients with Parkinson disease were randomly divided into study group 60 cases and control group 60 cases, control group was treated with levodopa therapy, study group was treated combined by pramipexole and levodopa levodopa. To observe the Parkinson＆#39;s Disease Rating Scale （UPDRS）, Hamilton Depression Scale （HAMD） and side reaction of two groups.Results：After the treatment, study group of 4 type UPDRS score were significantly lower than those in control group, HAMD score was significantly lower than control group, suggesting the study group patients with Parkinson＆#39;s disease symptoms were significantly lighter than the control group, depression significantly lighter than the control group （P〈0.05）.The adverse reaction during the treatment of study group was significantly lower than the control group （P〈0.01）.Conclusion：Levodopa combined with pramipexole has good clinical efficacy and safety treating in Parkinson＆#39;s disease, and is suitable for popularization and application.
出处
《中国医药导刊》
2014年第1期88-89,91,共3页
Chinese Journal of Medicinal Guide
关键词
普拉克索
左旋多巴
帕金森病
临床观察
Pramipexole
Levodopa
Parkinson＆#39
s disease
Clinical observation
